Meeting
2022 ASCO Annual Meeting
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.
Authors
Gonzalo Tapia
ICON Cancer Centre, University of Adelaide, Adelaide, SA, Australia
Gonzalo Tapia , Joanne Lundy , Gary Edward Richardson , Niky Zhao , Karen Ebsworth , Huibin Yue , Shichang Miao , Emil deGoma , Rita Jain , Thomas J. Schall , Kathleen Sullivan , Penglie Zhang , Paul L. de Souza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
ACTRN12621001342808
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2593)
DOI
10.1200/JCO.2022.40.16_suppl.2593
Abstract #
2593
Poster Bd #
248
Abstract Disclosures
Similar Posters
First Author: Daniel Wilhelm Mueller
Poster
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
First Author: Eugene R Ahn
Poster
2021 ASCO Annual Meeting
A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
First Author: Rachel E. Sanborn
Poster
2021 ASCO Annual Meeting
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
First Author: Sant P. Chawla